ZHEJIANG SHOUXIANGU PHARMACEUTICAL CO., LTD.

Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

603896

CNE100002XJ4

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-07-16 EDT			5-day change	1st Jan Change
22.92 ^CNY	+1.42%		+2.78%	-28.91%

07-12	Shouxiangu Pharmaceutical Gets Patent for Chinese Medicine Composition	MT
04-25	Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Nominates Zhou Chengguo as Director

January 10, 2018

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. in its first special Shareholders' Meeting of 2018 on January 11, 2018 approved the proposal of nominating Zhou Chengguo as director.

Latest news about Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

Shouxiangu Pharmaceutical Gets Patent for Chinese Medicine Composition	07-12	MT
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.(XSSC:603896) added to S&P Global BMI Index	23-09-18	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. agreed to acquire Hangzhou Yunhe Hengli Commercial Real Estate Co., Ltd from Hangzhou Yunhe Group Construction Management Co., Ltd. for CNY 0.001 million.	23-09-12	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-26	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-03	CI
Shouxiangu Pharma Unit Secures Re-Registration Approval for Three Drugs	23-01-17	MT
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-21	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-01-27	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.	21-10-12	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 4, 2020, has expired with 3,585,000 shares, representing 2.5% for CNY 165.08 million.	21-10-10	CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.	21-10-07	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-24	CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.	21-07-01	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-27	CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.	21-04-01	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-31	CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.	21-01-04	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. announces an Equity Buyback for 3,600,000 shares, for CNY 216 million.	20-11-03	CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-27	CI

Chart Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

More charts

Zhejiang Shouxiangu Pharmaceutical Co Ltd is a China-based company principally engaged in the breeding, cultivation, processing and sales of traditional Chinese medicinal materials, such as the ganoderma lucidums and dendrobium officinales. The Company's main products include ganoderma lucidum spore powder, Tiepi Fengdou granule, ganoderma extract products and fresh dendrobium officinales, among others. The Company mainly operates its businesses in domestic markets through wholesaling and direct sales.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

22.92 CNY

Average target price

55.6 CNY

Spread / Average Target

+142.58%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
ZHEJIANG SHOUXIANGU PHARMACEUTICAL CO., LTD.	-28.91%	626M
DONG-E-E-JIAO CO.,LTD.	+7.30%	4.69B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-31.08%	3.66B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.71%	3.11B
TASLY PHARMACEUTICAL GROUP CO., LTD	-24.32%	2.65B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-11.35%	2.28B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+34.19%	1.78B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+33.49%	1.37B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-15.07%	1.39B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK	+40.95%	1.38B

Alternative Medicine